ALXA Financial Facts
Interest expense: -2.05MNet loss attributable to Alexza common stockholders: -3.02M
See Full Income Statement
See Full Balance Sheet
Alexza Pharmaceuticals Inc. (ALXA) Earnings
|
Expand Research on ALXA
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +40.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -9.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/30/-1 | Q411 | -$0.13 | -$0.12 | -$0.01 | $1.88M | $5.8M | N/A |  | | Details | |
3/15/11  |
 |
Q410 | $0.42 | $0.09 | +$0.33 | $42.1M | $20.88M | N/A | | | Details |
| 5/9/11 |
|
Q111 | -$0.14 | -$0.21 | +$0.07 | $1.26M | $730K | N/A | | | Details |
| 8/8/11 |
|
Q211 | -$0.13 | -$0.15 | +$0.02 | $1.26M | $430K | N/A | | | Details |
| 11/7/11 |
|
Q311 | -$0.19 | -$0.14 | -$0.05 | $1.3M | $670K | N/A | | | Details |
| 5/10/12 |
Q112 | -$0.04 | -$0.08 | +$0.04 | $1.88M | $1.3M | N/A | | | Details | |
| 11/7/12 |
Q312 | -$0.52 | N/A | N/A | $729K | $1.86M | N/A | | | Details | |
| 3/26/13 |
Q412 | -$0.65 | N/A | N/A | $729K | $1.88M | N/A | | | Details |
